共 50 条
- [41] Redirected T-Cell Killing of Solid Cancers Targeted with an Anti-CD3/Trop-2-Bispecific Antibody Is Enhanced in Combination with Interferon-αMOLECULAR CANCER THERAPEUTICS, 2014, 13 (10) : 2341 - 2351Rossi, Edmund A.Rossi, Diane L.Cardillo, Thomas M.Chang, Chien-HsingGoldenberg, David M.
- [42] ANTI-CD3 - ANTI-IL-2 RECEPTOR (CD3,25) BISPECIFIC MONOCLONAL-ANTIBODY (BSMAB) - T-CELL IMMUNOMODULATION WITH REDUCED ACTIVATION AND TOXICITY THAN ANTI-CD3 MAB INVIVOJOURNAL OF IMMUNOLOGY, 1993, 150 (08): : A189 - A189MACLEAN, JASU, ZCOLVIN, RBWONG, JT
- [43] Vγ2 x PD-L1, a Bispecific Antibody Targeting Both the Vγ2 TCR and PD-L1, Improves the Anti-Tumor Response of Vγ2Vδ2 T CellFRONTIERS IN IMMUNOLOGY, 2022, 13Yang, RuiHe, QingZhou, HuiGong, ChengWang, XingSong, XingpanLuo, FangLei, YangNi, QianWang, ZiliXu, ShashaXue, YanZhang, ManWen, HaimeiFang, LijuanZeng, LiangYan, YongxiangShi, JianZhang, JingYi, JizuZhou, Pengfei
- [44] Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumorsNature Cancer, 2023, 4 : 485 - 501Fiore CattaruzzaAyesha NazeerMilton ToMikhail HammondCaitlin KoskiLucas Y. LiuV. Pete YeungDeena A. RennerfeldtAngela HenkensiefkenMichael FoxSharon LamKari M. MorrisseyZachary LangeVladimir N. PodustMika K. DerynckBryan A. IrvingVolker Schellenberger
- [45] Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumorsNATURE CANCER, 2023, 4 (04) : 485 - +Cattaruzza, FioreNazeer, AyeshaTo, MiltonHammond, MikhailKoski, CaitlinLiu, Lucas Y. Y.Yeung, V. PeteRennerfeldt, Deena A. A.Henkensiefken, AngelaFox, MichaelLam, SharonMorrissey, Kari M. M.Lange, ZacharyPodust, Vladimir N. N.Derynck, Mika K. K.Irving, Bryan A. A.Schellenberger, Volker
- [46] Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in combination with KN046, an anti-CTLA4/PD-L1 antibody, in patients with advanced HER2-positive nonbreast cancer: a combined analysis of a phase Ib and a phase II studySIGNAL TRANSDUCTION AND TARGETED THERAPY, 2025, 10 (01)Liu, DanGong, JifangLi, JianQi, ChangsongNiu, ZuoxingLiu, BoPeng, ZhiLuo, SuxiaWang, XichengWang, YakunZhao, RusenChen, LilinDeng, TingLi, ZhenChen, LeiFang, MeimeiYang, HongweiLu, LinzhiZhang, YanmingKang, FenglingXu, TingZhang, XiaotianShen, Lin
- [47] ADMINISTRATION OF INTERLEUKINS 2 AND 18 WITH ANTI-PD-L1 ANTIBODY SUPPRESSES LIVER TUMOR GROWTH BY INCREASING EARLY MEMORY CD8 T CELL NUMBERSHEPATOLOGY, 2023, 78 : S1929 - S1929Kimura, KiminoriKimura, MasamichiKohara, MichinoriOkamura, HarukiTanaka, Yoshimasa
- [48] The adenosine A2A receptor antagonist CPI-444 blocks adenosine-mediated T-cell suppression and exhibits antitumor activity alone and in combination with anti-PD-1 and anti-PD-L1CANCER RESEARCH, 2016, 76Willingham, StephenHo, PoLeone, RobertPiccione, EmilyChoy, CarmenHotson, AndrewBuggy, JosephPowell, JonathanMiller, Richard
- [49] Evaluation of the anti-tumor effects of an anti-Human Epidermal growth factor receptor 2 (HER2) monoclonal antibody in combination with CD11b+/Gr-1+myeloid cells depletion using a recombinant peptibody in 4 T1-HER2 tumor modelINTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 121Ramezani-Aliakbari, KhadijehKhaki-Bakhtiarvand, VahidMahmoudian, JafarAsgarian-Omran, HosseinShokri, FazelHojjat-Farsangi, MohammadJeddi-Tehrani, MahmoodShabani, Mahdi
- [50] Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)BLOOD, 2023, 142Hutchings, MartinMontesinos, PauSantoro, ArmandoHou, Hsin-AnMartinez-Sanchez, Maria PilarVives, SusanaGalimberti, SaraChen, Tsai-YunFrigeni, MarcoGarciaz, SylvainSalamero, OlgaYeh, Su-PengYee, KarenSchnetzler, GabrielBarata, TeresaSimon, SilkeHinton, HeatherKorfi, KooroshRichard, MurielKeshelava, NinoSubklewe, Marion